Susquehanna International Group, LLP Inhibrx, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	SELL	$32.76 - $39.56 $1 Million - $1.21 Million	-30,600 Reduced 49.59%	31,100 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $894,650 - $2.34 Million	61,700 New	61,700 $2.34 Million
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $725,888 - $1.19 Million	-42,800 Reduced 73.04%	15,800 $410,000
Q1 2023 May 16, 2023	BUY	$18.45 - $27.14 $732,465 - $1.08 Million	39,700 Added 210.05%	58,600 $1.11 Million
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $30,270 - $49,995	-1,500 Reduced 7.35%	18,900 $465,000

Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $236,232 - $504,492	20,400 New	20,400 $366,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $262,548 - $569,976	13,200 New	13,200 $294,000

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.